High affinity binding of cholecystokinin to small cell lung cancer cells

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Small cell lung cancer (SCLC) is a highly aggressive malignancy.
• Cholecystokinin (CCK) is a peptide hormone involved in various physiological processes.
• The presence and function of CCK receptors in SCLC remain largely uncharacterized.

Purpose of the Study:

• To investigate the binding characteristics of CCK receptors on SCLC cell lines.
• To determine the affinity and density of these receptors.
• To explore the potential role of CCK as a regulatory peptide in SCLC.

Main Methods:

• Radioligand binding assays using 125I-Bolton Hunter-cholecystokinin octapeptide (125I-BH-CCK-8).
• Characterization of binding kinetics, affinity (Kd), and receptor density (Bmax).
• Pharmacological profiling with various CCK analogs and related peptides.

Main Results:

• 125I-BH-CCK-8 demonstrated high-affinity binding (Kd = 2.4 nM) to a single class of sites (1700 sites/cell) on the NCI-H209 SCLC cell line.
• Binding was time-dependent with a specific to non-specific binding ratio of 8:1.
• Gastrin, caerulein, CCK-33, and nonsulfated CCK-8 potently inhibited 125I-BH-CCK-8 binding, while CCK-26-32-NH2 did not.

Conclusions:

• CCK receptors are present on small cell lung cancer cells.
• The high-affinity binding suggests a specific interaction between CCK and SCLC.
• CCK may play a significant role as a regulatory peptide in the pathogenesis or progression of SCLC.